37.51
-0.23 (-0.61%)
| Penutupan Terdahulu | 37.74 |
| Jumlah Dagangan | 1,324,883 |
| Harga / Buku (P/B) | 7.59 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -3.27 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.33% |
| Nisbah Semasa (MRQ) | 11.10 |
| Aliran Tunai Operasi (OCF TTM) | -134.37 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -79.65 M |
| Pulangan Atas Aset (ROA TTM) | -31.88% |
| Pulangan Atas Ekuiti (ROE TTM) | -52.20% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Pharvaris N.V. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.13 |
|
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 6.25% |
| % Dimiliki oleh Institusi | 89.49% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Foresite Capital Management Iv, Llc | 30 Jun 2026 | 4,778,581 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| LU PENG | - | 37.84 | -15,000 | -567,600 |
| Jumlah Keseluruhan Kuantiti Bersih | -15,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -567,600 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 37.84 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| LU PENG | Pegawai | 08 Sep 2026 | Jual automatik (-) | 15,000 | 37.84 | 567,600 |
| LU PENG | Pegawai | 08 Sep 2026 | Pelaksanaan pilihan | 15,000 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |